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Introduction
============

Despite recent advances in perinatal-neonatal care, there is a trend of increased incidence of bronchopulmonary dysplasia among survivors of prematurity.[@ref1] Most infants who develop bronchopulmonary dysplasia are born prematurely, and 75% of affected babies weigh less than 1000 g at birth.[@ref2] [@ref3] The risk of developing bronchopulmonary dysplasia increases with decreasing birth weight, with reported incidence as high as 85% in neonates weighing between 500 g and 699g, but only 5% in infants with birth weights over 1500 g.[@ref2] [@ref3] In the most immature infants, even minimal exposure to supplemental oxygen and mechanical ventilation could be enough to contribute to bronchopulmonary dysplasia.[@ref2] [@ref3] This puts a heavy burden on health resources because these infants are at risk of frequent hospital readmissions in the first two years after birth and, even as adolescents, have lung function abnormalities and persistent respiratory symptoms.[@ref4] [@ref5]

The lungs of very preterm infants are uniquely susceptible to injury because they are structurally immature, deficient in surfactant, and not supported by a stiff chest wall. Hence the lung of very preterm infants is easily damaged by mechanical ventilation.[@ref6] To maintain functional residual capacity and improve lung compliance and oxygenation, nasal continuous positive airway pressure (CPAP) has been advocated at the initiation of respiratory support.[@ref7] [@ref8] [@ref9] [@ref10] Observational studies in both the era before the widespread use of antenatal steroids and after the introduction of surfactant have documented an association between lower rates of bronchopulmonary dysplasia and increased use of nasal CPAP shortly after birth---that is, "primary" continuous positive airway pressure as a means of avoiding endotracheal intubation and mechanical ventilation.[@ref11] [@ref12] [@ref13] An observational study reported a lower rate of bronchopulmonary dysplasia with much greater use of nasal CPAP in one centre compared with seven other centres.[@ref11] Another study reported higher bronchopulmonary dysplasia rates in two Boston centres when compared with a single centre in New York (22% *v* 4%), with the higher rates in Boston associated with more use of mechanical ventilation (75% *v* 29%).[@ref12] Another retrospective study, of 261 preterm infants, that compared intubation and ventilation with primary nasal CPAP reported lower mortality and lower rates of administered surfactant, bronchopulmonary dysplasia, and intraventricular haemorrhage in infants who received nasal CPAP.[@ref13] In addition, a study compared rates of bronchopulmonary dysplasia, intubation in the delivery room, and mechanical ventilation for more than 24 hours in 14 tertiary level neonatal intensive care units in northern Italy.[@ref14] Centres with high delivery room intubation rates had higher rates of ventilation and bronchopulmonary dysplasia.[@ref14] These studies prompted the launch of large randomised controlled trials comparing nasal CPAP with endotracheal intubation soon after birth. We reviewed the available literature on the use of primary nasal CPAP soon after birth compared with intubation and mechanical ventilation for the prevention of death or bronchopulmonary dysplasia in very preterm infants.

Methods
=======

We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials using a predefined algorithm (see supplementary file), reviewed abstracts from annual meetings of the Pediatric Academic Society (2000-12), and performed a manual search of references in narrative and systematic reviews. Search terms included "infant", "newborn", "resuscitation", "continuous positive airway pressure", and "sustained inflation".

Study selection
---------------

We included studies if they were randomised controlled trials, compared nasal CPAP with endotracheal intubation as the primary mode of respiratory support after birth in preterm populations at less than 32 weeks' gestation, and presented the outcomes of either death or bronchopulmonary dysplasia (defined as the need for oxygen support or mechanical ventilation at 36 weeks corrected gestation) during hospital stay. Our primary outcome measure was death or bronchopulmonary dysplasia, or both, in a preterm population at less than 32 weeks' gestation. Secondary outcomes included the need for any mechanical ventilation during stay on a neonatal intensive care unit, treatment with surfactant, pneumothorax, postnatal corticosteroid treatment, intraventricular haemorrhage (grade III/IV or described as severe), any necrotising enterocolitis, any patent ductus arteriosus or any patent ductus arteriosus needing ligation, and any or severe retinopathy of prematurity. The review team resolved any discrepancies in inclusion through consensus.

Data extraction
---------------

Data were recorded using a standardised data collection form to record study design and methodological characteristics, patient characteristics, interventions, and outcomes, including the relative risks and 95% confidence intervals. We also documented information on mode of randomisation, allocation concealment, blinding, and intention to treat analysis. Two investigators (GMS, MK) independently extracted data and resolved discrepancies in consultation with another member of the review team (PYC).

Assessment of methodological quality
------------------------------------

We assessed the methodological quality of the included trials and evaluated risk of bias using elements of the Cochrane Collaboration tool.[@ref15] The domains used in the present systematic review pertained to randomisation and allocation concealment (selection bias), blinding (performance and detection bias), and adherence to the intention to treat principle (attrition bias).

Statistical analysis
--------------------

The principal summary measures were the weighted mean difference for continuous outcomes and relative risk and absolute risk reduction for dichotomous outcomes. For each trial we retrieved or calculated the crude relative risk and absolute risk reduction estimates and corresponding 95% confidence intervals for the assessed outcomes. We explored heterogeneity using a χ^2^ test and measured the quantity of heterogeneity with the I^2^ statistic.[@ref16] We used random effects models to summarise relative risk and absolute risk reduction estimates.[@ref17] Analyses were performed in RevMan version 5.2 (Cochrane Collaboration, 2013). All P values are two tailed. Where the pooled estimates of relative risk were statistically significant we calculated the numbers needed to treat (NNT) for all outcomes. The study is reported according to the PRISMA checklist.[@ref18]

Results
=======

Figure 1[](#fig1){ref-type="fig"} shows the flow of studies through the selection process. Our initial search identified 65 citations of potentially eligible studies, of which 50 were rejected based on a screening of the study title and abstract. Of the remaining 15 studies that were assessed in full text, four trials including 2780 infants[@ref7] [@ref8] [@ref9] [@ref10] fulfilled the inclusion criteria (table 1[](#tbl1){ref-type="table"}). Table 2[](#tbl2){ref-type="table"} presents an assessment of risk of bias for the included studies. All described adequate randomisation. We assessed all the studies as being at high risk of bias for blinding of participants and caregivers, as it was not feasible to do so for the type of interventions being compared; however, the studies did provide objective criteria for defining their primary outcome and failure of treatment. All the studies provided inhospital outcome data for the randomised participants, and infants in all the studies were analysed by intention to treat. The nasal CPAP and intubation groups were well matched; birth weight and gestational age did not differ significantly (table 1). Other aspects of respiratory treatment, including resuscitation devices used and criteria for using endotracheal intubation and surfactant, were adequately described in the studies and conformed to current international guidelines. Overall, 518/1296 infants in the nasal CPAP group required intubation within the first week after birth and 643/1296 infants in the nasal CPAP group and 1402/1486 in the intubation group received surfactant.

![**Fig 1** Flowchart for selection of eligible studies](schg012218.f1_default){#fig1}

###### 

 Characteristics of included randomised controlled studies. Values are means (standard deviations) unless stated otherwise

  Variables                  Morley (2008)^7^                      SUPPORT (2010)^8^                     Sandri (2010)^10^                     Dunn (2011)^9^
  -------------------------- ------------------------------------- ------------------------------------- ------------------------------------- -------------------------------------
  Total No of participants   610                                   1316                                  208                                   648\*
  Gestation (weeks)          25^0/7^-28^6/7^                       24^0/7^-27^6/7^                       25^0/7^-28^6/7^ weeks                 26^0/7^-29^6/7^
  CPAP group:                                                                                                                                  
   No in group               307                                   663                                   103                                   223
   Birth weight (g)          964 (212)                             834 (188)                             967 (221)                             1053 (252)
   Gestational age (weeks)   26.9 (1.0)                            26.2 (1.1)                            27.0 (1.0)                            28.1 (1.1)
  Intubation group:                                                                                                                            
   No in group               303                                   653                                   105                                   425
   Birth weight (g)          952 (217)                             825 (198)                             913 (200)                             1040 (244)
   Gestational age (weeks)   26.9 (1.0)                            26.2 (1.1)                            27.0 (1.0)                            28.0 (1.1)
  Timing of randomisation    After delivery                        Before delivery                       After delivery                        After delivery
  Stratification (weeks)     25^0/7^-26^6/7^ and 27^0/7^-28^6/7^   24^0/7^-25^6/7^ and 26^0/7^-27^6/7^   25^0/7^-26^6/7^ and 27^0/7^-28^6/7^   26^0/7^-27^6/7^ and 28^0/7^-29^6/7^

CPAP=continuous positive airway pressure.

\*Infants randomised to prophylactic surfactant group and intubate, surfactant, or extubate group were combined in the intubation group (prophylactic surfactant group, gestational age 28 (1.1 weeks) and birth weight 1040 g (244 g), intubate, surfactant, or extubate group gestational age 28.1 (1.1) and birth weight 1066 (270 g)).

###### 

 Assessment of risk of bias in included studies

  Study              Year   Random sequence generation   Allocation concealment   Blinding of participants and staff   Blinding of outcome assessment   Incomplete outcome data   Selective outcome reporting
  ------------------ ------ ---------------------------- ------------------------ ------------------------------------ -------------------------------- ------------------------- -----------------------------
  Morley et al^7^    2008   Low                          Low                      High                                 Unclear                          Low                       Low
  SUPPORT^8^         2010   Low                          Low                      High                                 Unclear                          Low                       Low
  Sandri et al^10^   2010   Low                          Low                      High                                 Unclear                          Low                       Low
  Dunn et al^9^      2011   Low                          Low                      High                                 Unclear                          Low                       Low

Table 3[](#tbl3){ref-type="table"} and figure 2[](#fig2){ref-type="fig"} show the pooled results for our primary outcome. All trials reported death or bronchopulmonary dysplasia independently at 36 weeks corrected gestation. A reduction of bronchopulmonary dysplasia occurred with borderline significance in favour of the nasal CPAP group: relative risk 0.91 (95% confidence interval 0.82 to 1.01), risk difference 0.03 (95% confidence interval −0.07 to 0.01, table 3, fig 2). Pooled analysis showed a significant benefit for the combined outcome of death or bronchopulmonary dysplasia, or both, at 36 weeks corrected gestation for babies treated with nasal CPAP: relative risk 0.91 (0.84 to 0.99), risk difference −0.04 (−0.07 to −0.00), NNT of 25 (fig 2).

![**Fig 2** Forest plot comparison of death or bronchopulmonary dysplasia (BPD), or both, at 36 weeks corrected gestation; death; and bronchopulmonary dysplasia at 36 weeks corrected gestation. CPAP=continuous positive airway pressure](schg012218.f2_default){#fig2}

###### 

 Results of primary and secondary outcomes. Values are numbers of participants unless stated otherwise

  Variables                                     No of studies (references)   Nasal CPAP group   Intubation group   Relative risk (95% CI)   Risk difference (95% CI)   Number needed to treat
  --------------------------------------------- ---------------------------- ------------------ ------------------ ------------------------ -------------------------- ------------------------
  Death at 36 weeks corrected gestation         4^7-10^                      145/1296           180/1486           0.88 (0.68 to 1.14)      −0.02 (−0.04 to 0.01)      
  BPD at 36 weeks corrected gestation           4^7-10^                      383/1182           461/1354           0.91 (0.82 to 1.01)      −0.03 (−0.07 to 0.01)      
  Death or BPD, or both                         4^7-10^                      532/1296           641/1486           0.91 (0.84 to 0.99)      −0.04 (−0.07 to −0.00)     25
  Received any mechanical ventilation           4^7-10^                      839/1296           1441/1486          0.56 (0.32 to 0.97)      −0.34 (−0.68 to −0.01)     
  Surfactant treatment                          4^7-10^                      643/1296           1402/1486          0.40 (0.23 to 0.70)      −0.51 (−0.79 to −0.23)     
  Pneumothorax                                  4^7-10^                      86/1296            78/1486            1.26 (0.51 to 3.09)      0.01 (−0.04 to 0.05)       
  Postnatal corticosteroid treatment            3^7\ 8\ 10^                  97/1041            137/1024           0.73 (0.49 to 1.10)      −0.04 (−0.07 to 0.00)      
  Intraventricular haemorrhage (grade III/IV)   4^7-10^                      133/1270           126/1445           1.1 (0.84 to 1.44)       0.00 (−0.03 to 0.03)       
  Any necrotising enterocolitis                 4^7-10^                      122/1286           115/1469           1.19 (0.93 to 1.52)      0.01 (−0.01 to 0.03)       
  Any patent ductus arteriosus                  3^7\ 9\ 10^                  251/632            321/832            1.06 (0.87 to 1.30)      0.03 (−0.06 to 0.11)       
  Patent ductus arteriosus needing ligation     2^7\ 10^                     50/410             60/408             0.83 (0.59 to 1.17)      −0.03 (−0.07 to 0.01)      
  Any retinopathy of prematurity                3^8-10^                      278/602            336/771            1.05 (0.80 to 1.36)      0.01 (−0.09 to 0.11)       
  Severe retinopathy of prematurity             3^8-10^                      87/806             83/941             1.22 (0.71 to 2.08)      0.01 (−0.02 to 0.05)       

CPAP=continuous positive airway pressure; BPD=bronchopulmonary dysplasia.

We identified significant heterogeneity for administered surfactant and any mechanical ventilation and therefore these results must be interpreted with caution. All trials assessed surfactant, with a significant reduction in administered surfactant in the nasal CPAP group (relative risk 0.40, 0.23 to 0.70, risk difference −0.51, −0.79 to −0.23, with 98% heterogeneity). All trials assessed the need for any mechanical ventilation, with a significant reduction in the nasal CPAP group (relative risk 0.56, 0.32 to 0.97, risk difference −0.34, −0.68 to −0.01, with 99% heterogeneity).

Other outcomes (including postnatal corticosteroid and patent ductus arteriosus) were not significantly different between those treated with nasal CPAP or with intubation (table 3). Subgroup analyses based on gestational age were not possible because the results of individual studies used different gestational ages for stratification. In addition, one trial was stopped after recruitment reached 74% of the projected sample size, owing to difficulties with enrolment.[@ref9]

Long term outcomes have been reported recently for the SUPPORT trial (Surfactant, Positive Pressure, and Pulse Oximetry Randomized Trial),[@ref8] and Dunn et al are planning to report their long term outcomes at two years corrected age.[@ref9] The SUPPORT trial did not show any difference in death or neurodevelopmental impairment at 18 to 22 months between groups.[@ref19]

Discussion
==========

We identified four randomised controlled trials that compared nasal CPAP with intubation,[@ref7] [@ref8] [@ref9] [@ref10] as they are somewhat difficult to undertake during the emergent timeframe of neonatal resuscitation. Our meta-analysis shows that one additional infant could survive to 36 weeks without bronchopulmonary dysplasia for every 25 babies treated with nasal continuous positive airway pressure (CPAP) in the delivery room rather than being intubated and mechanically ventilated. In addition, the reduction in bronchopulmonary dysplasia was of borderline significance.

However, caution should be exercised in generalising the results from our review. All the studies required antenatal consent, preselecting more stable pregnancies and lowering the observed incidence of acute or serious antenatal and neonatal complications. In addition, 95% of the infants included in our analysis received antenatal steroids. Furthermore, none of the studies were blinded, raising the possibility of bias influencing the outcomes if caregivers did not follow the trial guidelines or changed subsequent management based on resuscitation interventions. We did not conduct any formal tests for publication bias; however, funnel plots (data not shown) revealed no obvious asymmetry. Only one trial reported long term outcomes and reported no difference between the nasal CPAP group and the intubation group.[@ref19]

None of the trials enrolled infants of 23 weeks gestational age and only one trial included infants of 24 weeks gestational age.[@ref8] These extremely premature neonates represent a high risk group, with a high mortality and a high need for early intubation in the delivery room. A further confounder is the variation in how surfactant was administered between the identified studies. The thresholds for intubation and surfactant treatment varied from 40% to 60% oxygen, potentially influencing lung injury acutely (that is, pneumothorax) or chronically as bronchopulmonary dysplasia.

These studies were conducted when 21% oxygen was not recommended as the initial oxygen concentration used for neonatal resuscitation. In addition, the use of 100% oxygen in neonatal resuscitation has been associated with increased oxidative stress and related pulmonary injury.[@ref20] It will be interesting to examine if similar effects on mortality and morbidity are observed when nasal CPAP is compared with intubation and mechanical ventilation for extremely low birth weight infants using 21-40% fractional inspired oxygen for initiating resuscitation at birth. None the less, the rush to intubate and mechanically ventilate at birth could be avoided with the increasing knowledge of normal oxygen saturation levels in the first minutes after birth.[@ref21] [@ref22] [@ref23]

Despite these limitations, clinicians remain obliged to resuscitate newborn infants on the basis of best available evidence, and researchers should be encouraged to build on existing trials to deal with this important problem. The studies included in this review prove that large trials could be undertaken in the delivery room, with random allocation of all eligible babies.[@ref24] Future trials should investigate different levels of nasal CPAP and different strategies and thresholds for administering surfactant and should ensure long term follow-up of neurodevelopment. Waiver or deferral of consent might be considered as a means of avoiding selection bias and improving generalisability.

Conclusions
-----------

Nasal CPAP initiated in the delivery room compared with intubation reduces death or bronchopulmonary dysplasia in very preterm babies. One additional infant could survive to 36 weeks without bronchopulmonary dysplasia for every 25 babies treated with nasal CPAP in the delivery room rather than being intubated and mechanically ventilated.

### What is already known on this topic

1.  Most infants who develop bronchopulmonary dysplasia are born prematurely, and most of these babies weigh less than 1000 g at birth and are mechanically ventilated

2.  Providing nasal continuous positive airway pressure (CPAP) at birth has been advocated to avoid lung injury and potentially lessen the risk of bronchopulmonary dysplasia

### What this study adds

1.  One additional infant could survive to 36 weeks without bronchopulmonary dysplasia for every 25 babies treated with nasal CPAP in the delivery room rather than being intubated
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